Izotropic Corporation’s (CSE: IZO) (OTCQB: IZOZF) Leverages AI with Next-Gen Breast CT Imaging System

Core Insights - Izotropic Corporation is highlighted in an editorial by NetworkNewsWire, emphasizing its role in the AI-driven imaging sector targeting the breast cancer market [1][2]. Industry Overview - The healthcare sector is experiencing significant transformation due to artificial intelligence, particularly in medical imaging, which is crucial for breast cancer detection [2]. - Breast cancer is the most commonly diagnosed cancer among women globally, with over 2.3 million diagnoses and approximately 670,000 deaths reported by the World Health Organization in 2022 [2]. - In the United States, the American Cancer Society estimates 316,950 new invasive breast cancer cases for the current year [2]. Company Highlights - Izotropic Corporation is developing the IzoView Breast CT Imaging System, a specialized 3D imaging solution aimed at improving cancer detection accuracy, especially in women with dense breast tissue [3]. - The company focuses on innovative technologies and imaging products for more accurate screening, diagnosis, and treatment of breast cancers [4].